Close
Help
signup_email_alerts
Need Help?



Asymptomatic Pulmonary Hypertension in Systemic Lupus Erythematosus

Submit a Paper


Libertas Analytics


1110 Article Views

Publication Date: 28 Sep 2011

Journal: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders

Citation: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 2011:4 77-86

doi: 10.4137/CMAMD.S7667

CMIamd journal

86,518 Article Views

7,152,532 Libertas Article Views

More Statistics

Abstract

Introduction: Pulmonary arterial hypertension (PAH) is a serious and often fatal complication of systemic lupus erythematosus (SLE). Because the diagnosis of PAH often is made years after symptom onset, early diagnostic strategies are essential. Doppler echocardiography currently is considered the noninvasive screening test of choice for evaluating pulmonary hypertension.

Aim: Screening for asymptomatic pulmonary hypertension in systemic lupus erythematosus patients using Doppler echocardiography, and correlating it with inflammatory parameters of the disease.

Patients and methods: Doppler echocardiography was performed in 74 patients with systemic lupus erythematosus over one year (66 adult and 8 juvenile), adult SLE included 57 patients with adult-onset and 9 patients with childhood-onset. Pulmonary hypertension was diagnosed if the peak systolic pressure gradient at the tricuspid valve was more than 30 mmHg. All patients were subjected to full history taking, rheumatological examination, laboratory studies and chest x-ray.

Results: In seventy four SLE patients, the pulmonary hypertension was detected in 8 patients (10.8%), 7 adult-onset SLE patients (aged from 19 to 30 years) and 1 juvenile SLE (aged 12 years). The range of pulmonary artery systolic pressure was 34–61.2 mmHg (43.19 ± 9.28). No significant differences between patients with and those without pulmonary hypertension as regard clinical features. Significantly higher frequencies of rheumatoid factor and anti-cardiolipin antibodies were found in patients with pulmonary hypertension versus those without (P = 0.02, P = 0.008 respectively). Positive rheumatoid factor and ACL were significantly associated with occurrence of PAH in SLE (P = 0.007, P = 0.006 respectively). No significant correlations were found between pulmonary artery pressure, disease duration, SLE Disease Activity Index (SLEDAI), ESR, and anti-ds DNA.

Conclusion: Patients with SLE have an increased risk of pulmonary arterial hypertension. Echocardiography should be used as a screening tool in patients at high risk for development of pulmonary hypertension. Positive anti-cardiolipin antibodies and rheumatoid factor were significant predictors of pulmonary hypertension in our study.


Post a Comment

x close

Discussion Add A Comment

Posted by shereen - 16:41,September 29, 2011

All patients are asymptomatic, and they receive antiduretics only until they developed symptoms.

Posted by wellington ayensu - 14:38,September 29, 2011

Wonder if the PAH positives may have to follow different course of therapy for better maintenance.


share on

Our Service Promise

  • Prompt Processing (Less Than 3 Weeks)
  • Fair & Comprehensive Peer Review
  • Professional Author Service
  • Leading Editors in Chief
  • Extensive Indexing
  • High Readership & Impact
  • What Your Colleagues Say

Quick Links

Follow Us We make it easy to find new research papers.

BROWSE CATEGORIES
Our Testimonials
Recently we published a paper describing cloning of a new kinase gene, MLK4, in Genomics Insights. I was impressed by the prompt processing and  speed of publication.  The comments from the reviewers allowed me to improve the paper significantly.  The reviews were scientifically deep and objective, which is very valuable because in many journals decisions to publish or not to publish are very unfair and subjective. I highly recommend that other researchers publish their papers in Genomics Insights.
Dr Eugene R. Zabarovsky (Karolinska Institute, Stockholm, Sweden) What Your Colleagues Say